Shockwave Medical Inc (SWAV)

[Whalatane]

From an earlier PR

the plan, revealed on an earnings call following the approval announcement, is to price the Shockwave C2 at $4,700, which will be a standardized national price.

“We believe it is a novel, differentiated product that safely improves PCI outcomes, is easy to use, and expands the population of patients that cardiologists can safely treat. Further, the device price is a component of the IVL procedure costs, which CMS evaluates when determining both add-on and long-term payment levels,” Shockwave Medical’s Scott Shadiow told TCTMD. “We have set the C2 price at a level that we believe will optimize the future reimbursement of IVL. For near-term reimbursement, one of the benefits of being included in the FDA’s ‘Breakthrough’ program is its alignment with CMS’ NTAP [New Tech Add-On Payment] & TPT [Transitional Pass Through] reimbursement programs for inpatient and outpatient procedures. We have already submitted an application for [an] NTAP to CMS.

This device will pay for itself very quickly based on $3,666 per procedure ( including the Cath labs / interventionists time ) from Medicare

JMO
Kiwi